Welcome to our dedicated page for TenX Keane Acquisition news (Ticker: TENKU), a resource for investors and traders seeking the latest updates and insights on TenX Keane Acquisition stock.
The news feed for TENKU focuses on the public disclosures and transaction milestones of TenX Keane Acquisition, a blank check company formed to complete a business combination, and its merger with the oncology subsidiary of Citius Pharmaceuticals, Inc. News releases describe TenX Keane Acquisition’s initial public offering on Nasdaq, its trust account structure, and multiple extensions of the deadline to complete an initial business combination.
Subsequent coverage highlights the definitive agreement between TenX Keane Acquisition and the Citius oncology subsidiary to form Citius Oncology, Inc., a publicly listed company intended to trade under the symbol CTOR. Articles report that TenX shareholders approved the business combination at an extraordinary general meeting and outline how the transaction is structured, including the conversion of the subsidiary’s shares into common stock of Citius Oncology.
Because the target of TenX Keane Acquisition’s merger is an oncology-focused pharmaceutical company, the TENKU news stream also includes context from Citius Pharmaceuticals, Inc. regarding its oncology subsidiary and product candidate LYMPHIR, as described in joint press releases. These items explain how the merger is expected to support the development and commercialization of targeted oncology therapies through the Citius Oncology platform.
Investors and observers who follow TENKU-related news can use this page to review historical announcements about the SPAC’s formation, its financing and extension arrangements, shareholder votes, and the evolution toward Citius Oncology, Inc. For current operational updates, filings and press releases issued under the Citius Oncology, Inc. name provide more detailed information on the oncology business that emerged from the TenX Keane Acquisition transaction.
TenX Keane Acquisition has successfully priced its initial public offering (IPO) at $10.00 per unit, totaling 6,000,000 units. Each unit includes one ordinary share and a right to receive two-tenths of one ordinary share upon completing the Company's initial business combination. Trading under the ticker symbol TENKU begins on October 14, 2022, on the Nasdaq Global Market. The underwriter, Maxim Group LLC, has a 45-day option to purchase an additional 900,000 units. The offering is slated to close on October 18, 2022, pending customary closing conditions.